Natera, Inc., a global leader in cell-free DNA testing, announced that members of its management team will present at the following investor conferences: The Morgan Stanley 21st Annual Global Healthcare Conference on Monday, Sept. 11 at 4:55 p.m. ET in New York, NY The Baird 2023 Global Healthcare Conference on Tuesday, Sept.
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the following investor conferences:
- The Morgan Stanley 21st Annual Global Healthcare Conference on Monday, Sept. 11 at 4:55 p.m. ET in New York, NY
- The Baird 2023 Global Healthcare Conference on Tuesday, Sept. 12 at 4:20 p.m. ET in New York, NY
A live webcast and audio archive of each event may be accessed through the investor relations section of the Natera website at investor.natera.com. Replays will be available shortly thereafter.
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 150 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230901916970/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com
Source: Natera, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20230901916970/en
